US Drug Recall Register
Class III · Low risk Terminated Initiated Aug 6, 2013 (13 years ago)

Maalox Regular Strength Antacid

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Labeling: Incorrect Or Missing Lot and/or Exp Date: The lot number and/or expiration date may be illegible on the outer plastic bottle packaging.

What was recalled

Maalox Regular Strength Antacid (calcium carbonate) chewable tablets, 600 mg, Wild Berry flavor, packaged in a) 50-count (UPC 0 58478 44825 1), b) 100-count (UPC 0 58478 44826 8) and c) 145-count (UPC 0 58478 44836 7) tablets per bottle, Novartis Consumer Health Canada Inc., Mississauga, ON L5N 2X7, foreign labeling containing English and French, NPN 02238290.

Recalling firm
Novartis Consumer Health
Origin
NE, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-903-2013

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Carbonate recalls

See all
Class II · Moderate risk Ongoing

TopCare health

Reason Presence of foreign substance: small metallic particles in chewable tablets.

Guardian Drug Co. Inc. NDC 76162-129-68 D-0579-2026
Class II · Moderate risk Ongoing

TopCare health

Reason Presence of foreign substance: small metallic particles in chewable tablets.

Guardian Drug Co. Inc. NDC 76162-128-22 D-0578-2026
Class II · Moderate risk Ongoing

EQUALINE ultra strength

Reason Presence of foreign substance: small metallic particles in chewable tablets.

Guardian Drug Co. Inc. NDC 41163-171-68 D-0577-2026
Class II · Moderate risk Ongoing

EQUALINE extra strength

Reason Presence of foreign substance: small metallic particles in chewable tablets.

Guardian Drug Co. Inc. NDC 41163-129-22 D-0576-2026
Class II · Moderate risk Ongoing

GOODSENSE Ultra Strength

Reason Presence of foreign substance: small metallic particles in chewable tablets.

Guardian Drug Co. Inc. NDC 50804-171-68 D-0575-2026